Prof. Eva Segelov

Professor Eva Segelov – Australia MBBS (Hons 1) PhD FRACP Professor/Director of Oncology Monash Health and Monash University, Clayton, Melbourne VIC. Australia

eva.segelov@monash.edu

Eva’s interest is in clinical trials and associated translational research, particularly involving establishing and fostering international collaborations. She is the Principal Investigator of the international ICECREAM Phase II study; a Co-Chair of the international Phase III ASCOLT trial (aspirin v placebo as adjuvant therapy) and Chair of the translational study committee for ASCOLT; the Australian PI of the international Phase III QUASAR2 trial (role of bevacizumab as adjuvant therapy for colorectal cancer); the Australian co-PI of the international Phase III SCOT trial (duration of adjuvant therapy for CRC) and International Chair of the SCOT Translational Research Committee, Senior Australian PI of the international InterACCT study (metastatic anal cancer). She sits on the International Study of Rare Cancers Initiative Committee (anal cancer).

Eva has an interest in mentorship and novel approaches to interactive and interdisciplinary professional development and was awarded the prestigious UNSW Vice Chancellors award for Teaching Excellence in 2006. She has developed the novel Preceptorship model in the fields of Colorectal Cancer, Prostate Cancer and Lung Cancer, presenting the context of current cancer treatment through review of seminal clinical trials, which has engaged >300 registrars and junior consultants in mentor-led peer learning.

Eva has been the Convenor of multiple national meetings including the Clinical Oncological Society of Australia Annual Scientific Meetings 2007- 2009 and currently is Convenor of the Annual Scientific Meeting of the AGITG (2015-2020). She was a key member of the convening committee of the COBRA International Breast Cancer Controversies Meeting (2015) and the Convenor of the national Test Tailor Treat meeting in 2012.

Eva is a Chief Investigator on a number of NHMRC and Cancer Australia/Bowel Cancer Foundation Grants and is a member of the TransTasman Radiation Oncology Group International Data Safety Monitoring Committee. Editorial roles include member of Editorial Board of Journal of Global Oncology and Oncology Editor for Medicine Today.

She is a co-founder of CommNETs, bringing together a true international partnership of clinicians, researchers and patients/advocates to perform strategic research in the field of Neuroendocrine Tumours based on priorities established by rigorous consensus processes.

Share